JP2006504701A - 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 - Google Patents

眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 Download PDF

Info

Publication number
JP2006504701A
JP2006504701A JP2004539362A JP2004539362A JP2006504701A JP 2006504701 A JP2006504701 A JP 2006504701A JP 2004539362 A JP2004539362 A JP 2004539362A JP 2004539362 A JP2004539362 A JP 2004539362A JP 2006504701 A JP2006504701 A JP 2006504701A
Authority
JP
Japan
Prior art keywords
grams
ophthalmic composition
aqueous ophthalmic
acetylcarnosine
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004539362A
Other languages
English (en)
Japanese (ja)
Inventor
マーク・エー・バビザイェフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2006504701A publication Critical patent/JP2006504701A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
JP2004539362A 2002-09-30 2003-09-29 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 Pending JP2006504701A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41435702P 2002-09-30 2002-09-30
PCT/IB2003/004259 WO2004028536A1 (en) 2002-09-30 2003-09-29 Method for topical treatment of eye disease and composition and device for said treatment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010233468A Division JP2011037892A (ja) 2002-09-30 2010-10-18 治療手段
JP2010233467A Division JP2011037891A (ja) 2002-09-30 2010-10-18 薬剤組成物の製造のための水性眼科用組成物の使用、及び水性眼科用組成物

Publications (1)

Publication Number Publication Date
JP2006504701A true JP2006504701A (ja) 2006-02-09

Family

ID=32043384

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004539362A Pending JP2006504701A (ja) 2002-09-30 2003-09-29 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段
JP2010233467A Pending JP2011037891A (ja) 2002-09-30 2010-10-18 薬剤組成物の製造のための水性眼科用組成物の使用、及び水性眼科用組成物
JP2010233468A Pending JP2011037892A (ja) 2002-09-30 2010-10-18 治療手段

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010233467A Pending JP2011037891A (ja) 2002-09-30 2010-10-18 薬剤組成物の製造のための水性眼科用組成物の使用、及び水性眼科用組成物
JP2010233468A Pending JP2011037892A (ja) 2002-09-30 2010-10-18 治療手段

Country Status (4)

Country Link
US (3) US7795203B2 (enExample)
EP (1) EP1551399A4 (enExample)
JP (3) JP2006504701A (enExample)
WO (1) WO2004028536A1 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009190972A (ja) * 2008-02-12 2009-08-27 Snow Brand Milk Prod Co Ltd 白内障予防剤
JP2011037891A (ja) * 2002-09-30 2011-02-24 Mark A Babizhayev 薬剤組成物の製造のための水性眼科用組成物の使用、及び水性眼科用組成物
JP2014514328A (ja) * 2011-04-26 2014-06-19 レトロトップ、 インコーポレイテッド 酸化的網膜疾患
JP2017149711A (ja) * 2016-02-22 2017-08-31 参天製薬株式会社 ドルゾラミドとブリモニジンを含む医薬組成物
JP2017525735A (ja) * 2014-09-04 2017-09-07 ニコックス サイエンス アイルランド 一酸化窒素供与カルノシン化合物
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
US10058612B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
US10154978B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Disorders implicating PUFA oxidation
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
JP2021512172A (ja) * 2018-01-23 2021-05-13 セインダ ファーマシューティカル グアンジョウ コーポレイション 眼科的薬学的組成物、その調製方法、およびその適用
US11447441B2 (en) 2015-11-23 2022-09-20 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US11779910B2 (en) 2020-02-21 2023-10-10 Biojiva Llc Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
WO2024135853A1 (ja) 2022-12-23 2024-06-27 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 間葉系幹細胞又はその培養上清の利用
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2025104978A1 (ja) 2023-11-13 2025-05-22 国立大学法人 東京大学 ネクロプトーシス制御剤
US12673037B2 (en) 2021-02-05 2026-07-07 Biojiva Llc Methods of treating amyotrophic lateral sclerosis

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147816B2 (en) 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US7914815B2 (en) 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
WO2004058289A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
EP1586332A4 (en) * 2003-01-20 2009-11-11 Innovative Vision Products Inc COMBINED USE OF CARNOSINAS INHIBITOR WITH L-CARNOSINES AND COMPOSITION
EP1761272B1 (en) 2004-06-08 2013-04-24 Flamma S.P.A. Compositions containing d-carnosine
JP2006131580A (ja) * 2004-11-09 2006-05-25 Rohto Pharmaceut Co Ltd 粘膜適用組成物
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
KR101389300B1 (ko) 2005-02-14 2014-04-25 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈
TW200722109A (en) * 2005-03-31 2007-06-16 Bausch & Lomb Polysaccharide and polyol composition for treating dry eye and related methods of manufacture and methods of use
TWI393567B (zh) * 2005-03-31 2013-04-21 博士倫公司 治療乾眼之組合物及相關之製造方法及使用方法
US9052529B2 (en) 2006-02-10 2015-06-09 Johnson & Johnson Vision Care, Inc. Comfortable ophthalmic device and methods of its production
US7776364B2 (en) 2006-03-24 2010-08-17 Advanced Scientific, Llc Non-surgical method for treating cataracts in mammals including man
US20120122815A1 (en) * 2006-03-28 2012-05-17 Erning Xia Composition for Treating Dry Eye and Related Methods of Manufacture and Methods of Use
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
NL2002214C2 (en) * 2008-11-17 2010-05-18 Louis Johan Wagenaar Contact lens care solution.
US9308070B2 (en) 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
US20110111031A1 (en) * 2009-04-20 2011-05-12 Guang-Liang Jiang Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
ES2579173T3 (es) 2009-06-15 2016-08-05 Encore Health, Llc Ésteres de colina para tratar presbicia y cataratas
EP3069612A3 (en) 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PL2787968T3 (pl) 2011-12-07 2020-08-24 Allergan, Inc. Wydajne dostarczanie lipidów do ludzkiego filmu łzowego z użyciem wrażliwego na sól układu emulsyjnego
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
CA2934448A1 (en) 2012-12-20 2014-06-26 Rajiv Bhushan Antimicrobial compositions
KR102276326B1 (ko) 2013-03-13 2021-07-13 앙테이스 에스.아. 피부 회춘을 위한 펩타이드 및 이것을 사용하는 방법
PT3613423T (pt) 2013-07-10 2022-12-07 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
AU2014332488B2 (en) 2013-10-09 2017-03-09 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
EP3113613A4 (en) * 2014-03-03 2019-03-13 Encore Vision, Inc. LIPOIC ACID CHOLINESTER COMPOSITIONS AND METHOD OF USE THEREOF
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US12472157B2 (en) 2014-11-07 2025-11-18 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with n-acetylcysteine amide
US12667548B2 (en) 2014-11-07 2026-06-30 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide
KR102487299B1 (ko) 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
KR101690539B1 (ko) 2015-07-30 2016-12-29 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
PT3352766T (pt) 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
WO2017055924A2 (en) 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
WO2017147470A1 (en) * 2016-02-26 2017-08-31 The Regents Of The University Of California Bicontinuous microemulsions and methods of use thereof
WO2017178892A2 (en) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
MX390707B (es) 2017-01-31 2025-03-21 Kimberly Clark Co Composición antibacteriana que incluye un éster del ácido benzoico y métodos de inhibición del crecimiento bacteriano mediante el uso de la misma.
US11077150B2 (en) * 2018-10-09 2021-08-03 Massoumeh Kharazmi Methods and compositions for treatment of eye conditions
CN113226349A (zh) 2018-10-19 2021-08-06 激流生物科学有限公司 抗微生物肽及其使用方法
AU2020206139A1 (en) 2019-01-11 2021-07-29 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with N-acetylicysteine amide (NACA) or 2R,2R')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (diNACA)
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
JP7631200B2 (ja) 2019-01-11 2025-02-18 ナキュイティ ファーマシューティカルズ， インク． 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
US20220272987A1 (en) * 2019-04-12 2022-09-01 Jeffrey H. ROBBINS Composition including effervescent agents, biostimulant, nutrient, and pesticide
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
CN119997951A (zh) * 2022-09-19 2025-05-13 西姆莱斯股份公司 一种预防、缓解和/或治疗ptgs2诱发的皮肤紊乱及相关功能障碍的方法
KR102513994B1 (ko) * 2022-10-26 2023-03-24 김태윤 반려동물의 눈물 착색예방용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010294A1 (en) * 1993-10-15 1995-04-20 Bruschettini S.R.L. Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
WO2002060495A1 (en) * 2001-01-09 2002-08-08 Louis Johan Wagenaar Procedure and composition of treatment and/or care of the eye

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188266C (nl) * 1975-07-29 1992-05-18 Merck & Co Inc Werkwijze ter bereiding van een oogheelkundig inplantaat.
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS57108072A (en) * 1980-12-18 1982-07-05 Ajinomoto Co Inc Preparation of n-acylcarnosine
JPS57203440A (en) * 1981-06-11 1982-12-13 Nihon Contact Lens Seizou Kk Treating tool
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
JPS6471822A (en) * 1987-09-12 1989-03-16 Rohto Pharma Ophthalmic sustained release preparation
US5496820A (en) 1988-10-20 1996-03-05 Peraelampi; Markku Ophthalmic use of S-timolol hemihydrate
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
IT1260467B (it) * 1992-01-29 1996-04-09 Bruschettini Srl Medicamento contenente arg-gly-asp per il trattamento del glaucoma
JPH06211665A (ja) * 1993-01-19 1994-08-02 Rohto Pharmaceut Co Ltd ジラゼプを必須成分とする眼圧降下剤
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
RU2100020C1 (ru) 1993-06-23 1997-12-27 Лейрас Ой Средство для местного лечения глазной гипертензии и глаукомы и способ его получения
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
AU5084693A (en) * 1993-08-20 1995-03-21 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
AU3609795A (en) * 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
JPH0920648A (ja) * 1995-06-30 1997-01-21 Zenichi Ogita 外用剤
JPH1017488A (ja) * 1996-06-25 1998-01-20 Asahi Glass Co Ltd 緑内障治療薬
WO1998032435A1 (en) * 1997-01-29 1998-07-30 Braswell, A., Glenn Liquid eye drop composition
RU2114587C1 (ru) 1997-03-27 1998-07-10 Малое государственное предприятие "Научно-экспериментальное производство" Раствор для защиты роговицы от повреждений "визитон-1"
JPH1171282A (ja) * 1997-09-01 1999-03-16 Senju Pharmaceut Co Ltd 点眼用水性製剤
ATE258791T1 (de) * 1999-11-09 2004-02-15 Alcon Inc Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
AU2001236909A1 (en) * 2000-02-11 2001-08-20 Duke University Method of treating disorders of the eye
RU2171107C1 (ru) 2000-04-25 2001-07-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Глазные капли
US6503892B2 (en) * 2000-04-26 2003-01-07 New England Medical Center Hospitals Inc. Method of using matrix metalloproteinase inhibitors in filtering blebs following glaucoma filtering surgery and in the treatment of ischemic damage to the retina and optic nerve
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
IT1318640B1 (it) * 2000-07-25 2003-08-27 Univ Catania Derivati di carnosina, procedimento per la loro preparazione ecomposizioni farmaceutiche che li contengono.
JP2003171276A (ja) * 2001-11-30 2003-06-17 Menicon Co Ltd 眼精疲労改善眼科用組成物
US7795203B2 (en) * 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010294A1 (en) * 1993-10-15 1995-04-20 Bruschettini S.R.L. Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
WO2002060495A1 (en) * 2001-01-09 2002-08-08 Louis Johan Wagenaar Procedure and composition of treatment and/or care of the eye

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037891A (ja) * 2002-09-30 2011-02-24 Mark A Babizhayev 薬剤組成物の製造のための水性眼科用組成物の使用、及び水性眼科用組成物
JP2011037892A (ja) * 2002-09-30 2011-02-24 Mark A Babizhayev 治療手段
JP2009190972A (ja) * 2008-02-12 2009-08-27 Snow Brand Milk Prod Co Ltd 白内障予防剤
US11510888B2 (en) 2009-10-30 2022-11-29 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
USRE49238E1 (en) 2009-10-30 2022-10-11 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
JP2014514328A (ja) * 2011-04-26 2014-06-19 レトロトップ、 インコーポレイテッド 酸化的網膜疾患
US12156860B2 (en) 2011-04-26 2024-12-03 Biojiva Llc Disorders implicating PUFA oxidation
JP2017125046A (ja) * 2011-04-26 2017-07-20 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 酸化的網膜疾患
US10058522B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
US10058612B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
US10154978B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Disorders implicating PUFA oxidation
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
US11285125B2 (en) 2011-04-26 2022-03-29 Retrotope, Inc. Oxidative retinal diseases
US11241409B2 (en) 2011-04-26 2022-02-08 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
JP2017525735A (ja) * 2014-09-04 2017-09-07 ニコックス サイエンス アイルランド 一酸化窒素供与カルノシン化合物
US12060324B2 (en) 2015-11-23 2024-08-13 Biojiva Llc Site-specific isotopic labeling of 1,4-diene systems
US11453637B2 (en) 2015-11-23 2022-09-27 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US11447441B2 (en) 2015-11-23 2022-09-20 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
JP2017149711A (ja) * 2016-02-22 2017-08-31 参天製薬株式会社 ドルゾラミドとブリモニジンを含む医薬組成物
WO2017146036A1 (ja) * 2016-02-22 2017-08-31 参天製薬株式会社 ドルゾラミドとブリモニジンを含む医薬組成物
JP7418351B2 (ja) 2018-01-23 2024-01-19 セインダ ファーマシューティカル グアンジョウ コーポレイション 眼科的薬学的組成物、その調製方法、およびその適用
JP2021512172A (ja) * 2018-01-23 2021-05-13 セインダ ファーマシューティカル グアンジョウ コーポレイション 眼科的薬学的組成物、その調製方法、およびその適用
US11779910B2 (en) 2020-02-21 2023-10-10 Biojiva Llc Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US12673037B2 (en) 2021-02-05 2026-07-07 Biojiva Llc Methods of treating amyotrophic lateral sclerosis
WO2024135853A1 (ja) 2022-12-23 2024-06-27 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 間葉系幹細胞又はその培養上清の利用
EP4640838A1 (en) 2022-12-23 2025-10-29 Cell Exosome Therapeutics Inc. Utilization of mesenchymal stem cells or culture supernatant thereof
WO2025104978A1 (ja) 2023-11-13 2025-05-22 国立大学法人 東京大学 ネクロプトーシス制御剤

Also Published As

Publication number Publication date
US7795203B2 (en) 2010-09-14
JP2011037891A (ja) 2011-02-24
US9044425B2 (en) 2015-06-02
JP2011037892A (ja) 2011-02-24
US20110245177A1 (en) 2011-10-06
EP1551399A4 (en) 2011-01-05
US20100317586A1 (en) 2010-12-16
US20040192647A1 (en) 2004-09-30
EP1551399A1 (en) 2005-07-13
WO2004028536A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
US9044425B2 (en) Method for topical treatment of eye disease and composition and device for said treatment
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
JPS62501002A (ja) 高い眼圧の防止法、緑内障の処置及び高眼圧の処置
CN114796205B (zh) 用于治疗近视的方法和药物组合物
WO2006064672A1 (ja) 眼疾患治療剤
WO2007007894A1 (ja) キサンタンガムおよびテルペノイドを含有する点眼剤
CN115634226B (zh) 一种采用长春西汀治疗近视的方法
Singh et al. In vitro and in vivo evaluation of stimuli sensitive hydrogel for ophthalmic drug delivery
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
CN100563628C (zh) 一种苄达赖氨酸眼用凝胶制剂及其制备方法
CN116270442B (zh) 一种用于矫正近距离视力的眼用制剂
JPH10218792A (ja) アンギオテンシン変換酵素阻害薬を有効成分とする涙液分泌促進および角結膜障害治療剤
HK40109101A (en) A pharmaceutical composition for effectively delaying and treating myopia
HK40086794B (en) Method for treating myopia by vinpocetine
HK40086794A (en) Method for treating myopia by vinpocetine
WO2020152527A1 (en) Ophthalmic pharmaceutical compositions based on vitamins, amino acids and minerals for treating immature cataract
US20080261893A1 (en) Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
HK40069144A (en) Methods and pharmaceutical compositions for treating myopia
HK40069144B (en) Methods and pharmaceutical compositions for treating myopia
KR0159640B1 (ko) 도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형
CN115645420A (zh) 甘露糖及其药用衍生物在制备预防和/或治疗年龄相关性黄斑变性的药物中的应用
BR112020018377A2 (pt) Métodos de uso e composições farmacêuticas de um inibidor de syk seletivo

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120528